M B And K Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 19-12-2024
- Paid Up Capital ₹ 0.52 M
as on 19-12-2024
- Company Age 31 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.00 M
as on 19-12-2024
- Revenue -11.46%
(FY 2019)
- Profit -44.08%
(FY 2019)
- Ebitda 43.94%
(FY 2019)
- Net Worth 3.17%
(FY 2019)
- Total Assets -4.30%
(FY 2019)
About M B And K Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.52 M.
The company currently has active open charges totaling ₹4.00 M.
Shubh Khanna, Jaya Khanna, Roma Khanna, and Two other members serve as directors at the Company.
- CIN/LLPIN
U85110UP1993PTC015566
- Company No.
015566
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Jul 1993
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Varanasi, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at M B And K Pharma?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shubh Khanna  | Director | 11-Oct-2020 | Current |
| Jaya Khanna | Director | 01-Apr-2009 | Current |
| Roma Khanna | Director | 01-Apr-2009 | Current |
| Manoj Khanna | Director | 09-Nov-2001 | Current |
| Manish Khanna | Director | 09-Nov-2001 | Current |
Financial Performance of M B And K Pharma.
M B And K Pharma Private Limited, for the financial year ended 2019, experienced significant reduction in revenue, with a 11.46% decrease. The company also saw a substantial fall in profitability, with a 44.08% decrease in profit. The company's net worth moved up by a moderate rise of 3.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of M B And K Pharma?
In 2019, M B And K Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
L P Distributors Private LimitedActive 22 years 2 monthsShubh Khanna, Jaya Khanna and 3 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Union Bank Of India Creation Date: 24 Mar 2000 | ₹2.00 M | Open |
Union Bank Of India Creation Date: 24 Mar 2000 | ₹2.00 M | Open |
How Many Employees Work at M B And K Pharma?
Unlock and access historical data on people associated with M B And K Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of M B And K Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped M B And K Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
